Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EPS (Weighted Average and Diluted) (2020 - 2025)

Fulcrum Therapeutics (FULC) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.31 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 14.81% to -$0.31 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.18, a 555.56% decrease, with the full-year FY2025 number at -$1.18, down 637.5% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.31 for Q4 2025 at Fulcrum Therapeutics, roughly flat from -$0.31 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.87 in Q2 2024 to a low of -$664.12 in Q4 2021.
  • A 5-year average of -$35.3 and a median of -$0.4 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 328.95% in 2024, then crashed 132.18% in 2025.
  • Fulcrum Therapeutics' EPS (Weighted Average and Diluted) stood at -$664.12 in 2021, then surged by 99.93% to -$0.47 in 2022, then grew by 14.89% to -$0.4 in 2023, then soared by 32.5% to -$0.27 in 2024, then dropped by 14.81% to -$0.31 in 2025.
  • Per Business Quant, the three most recent readings for FULC's EPS (Weighted Average and Diluted) are -$0.31 (Q4 2025), -$0.31 (Q3 2025), and -$0.28 (Q2 2025).